

Appendix 2: Reference list of included articles.

1. Altman DG. Poor-quality medical research - What can journals do? *JAMA* 2002;287:2765-7.
2. Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE. Screening mammography in women 40 to 49 years of age: A systematic review for the American College of Physicians. *Ann Intern Med* 2007;146:516-26.
3. Autier P, Hery C, Haukka J, Boniol M, Byrnes G. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. *J Clin Oncol* 2009;27:5919-23.
4. Barratt A, Trevena L, Davey HM, McCaffery K. Use of decision aids to support informed choices about screening. *BMJ* 2004;329:507-10.
5. Barry MJ, Mulley AJ, Jr. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important? *JNCI* 2009;101:362-3.
6. Begg CB. The mammography controversy. *Oncologist* 2002;7:174-6.
7. Berlin L. Breast cancer, mammography, and malpractice Litigation: The controversies continue. *Am J Roentgenol* 2003;180:1229.
8. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. *N Engl J Med* 2005;353:1784-92.
9. Bjurstam N, Bjorneld L, Warwick J, Sala E, Duffy SW, Nystrom L, et al. The Gothenburg Breast Screening Trial. *Cancer* 2003;97:2387-96.
10. Bonneux L. Update on effects of screening mammography. *Lancet* 2002;360:337-8.
11. Bonneux L. Cardiovascular risk models. *BMJ* 2007;335:107-8.
12. Bordoni A, Probst-Hensch NM, Mazzucchelli L, Spitale A. Assessment of breast cancer opportunistic screening by clinical-pathological indicators: a population-based study. *Br J Cancer* 2009;101:1925-31.
13. Boyle P. Current situation of screening for cancer. *Ann Oncol* 2002;13:189-98.
14. Boyle P. Global summit on mammographic screening. *Ann Oncol* 2003;14:1159-60.
15. Boyle P. Mammographic breast cancer screening: after the dust has settled. *Breast* 2003;12:351-6.
16. Brant-Zawadzki M. CT screening: Why I do it. *Am J Roentgenol* 2002;179:319-26.
17. Brawley OW, Kramer BS. Cancer screening in theory and in practice. *J Clin Oncol* 2005;23:293-300.

18. Brody JG, Rudel RA, Michels KB, Moysich KB, Bernstein L, Attfield KR, et al. Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for prevention? *Cancer* 2007;109(12 Suppl):2627-34.
19. Buiatti E, Barchielli A, Bartolacci S, Federico M, De Lisi V, Bucchi L, et al. The impact of organised screening programmes on the stage-specific incidence of breast cancer in some Italian areas. *Eur J Cancer* 2003;39:1776-82.
20. Buist DSM, Aiello EJ, Miglioretti DL, White E. Mammographic breast density, dense area, and breast area differences by phase in the menstrual cycle. *Cancer Epi Biom* 2006;15:2303-6.
21. Buist DSM, Porter PL, Lehman C, Taplin SH, White E. Factors contributing to mammography failure in women aged 40-49 years. *JNCI* 2004;96:1432-40.
22. Bulliard JL, Levi F. Women's perception of mammography screening. *Int J Epidemiol* 2004;33:903-4.
23. Bunnell CA, Winer EP. Lumping versus splitting: The splitters take this round. *J Clin Oncol* 2002;20:3576-7.
24. Burke JP, Barry M, Kell MR. More on screening mammography. *N Engl J Med* 2011;364:281-2.
25. Burke JP, Power C, Gorey TF, Flanagan F, Kerin MJ, Kell MR. A comparative study of risk factors and prognostic features between symptomatic and screen detected breast cancer. *Eur J Surg Onc* 2008;34:149-53.
26. Charatan F. US panel finds insufficient evidence to support mammography. *BMJ* 2002;324:255.
27. Chlebowski RT, Anderson GL. The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. *JNCI* 2011;103:284-5.
28. Coebergh JW. Early breast cancer in Europe: progress and pitfalls in detection and management at the start of the new century. *Eur J Cancer* 2003;39:1645-7.
29. Crystal P, Strano SD, Shcharynski S, Koretz MJ. Using sonography to screen women with mammographically dense breasts. *Am J Roentgenol* 2003;181:177-82.
30. Das B, Feuer EJ, Mariotto A. Geographic association between mammography use and mortality reduction in the US. *Cancer Causes Contr* 2005;16:691-9.
31. Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, et al. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. *Br J Cancer* 2009;101:1338-44.
32. Day NE. The NHS breast cancer screening programme. *Br J Cancer* 2003;89:1.
33. Dickersin K, Tovey D, Wilcken N, Ghersi D. The background review for the USPSTF recommendation on screening for breast cancer. *Ann Intern Med* 2010;152:537.

34. Dillon MF, Hill ADK, Quinn CM, O'Doherty A, Crown J, Fleming FJ, et al. Surgical intervention in screen-detected patients versus symptomatic patients with breast cancer. *J Med Screen* 2004;11:211.
35. Dixon-Woods M, Baum M, Kurinczuk JJ. Screening for breast cancer with mammography. *Lancet* 2001;358:2166-7.
36. Djulbegovic B, Lyman GH. Screening mammography at 40-49 years: regret or no regret? *Lancet* 2006;368:2035-7.
37. Domenighetti G, D'Avanzo B, Egger M, Berrino F, Perneger T, Mosconi P, et al. Women's perception of the benefits of mammography screening: population-based survey in four countries. *Int J Epidemiol* 2003;32:816-21.
38. du Bois A. Mammographic screening: no reliable supporting evidence? *Lancet* 2002;360:719-20.
39. Duffy SW. Some current issues in breast cancer screening. *J Med Screen* 2005;12:128-33.
40. Duffy SW, Tabar L, Chen HH, Holmqvist M, Yen MF, Abdsalah S, et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties - A collaborative evaluation. *Cancer* 2002;95:458-69.
41. Duffy SW, Tabar L, Smith RA. The mammographic screening trials: Commentary on the recent work by Olsen and Gøtzsche. *J Surg Oncol* 2002;81:159-62.
42. Duffy SW, Tabar L, Smith RA. The mammographic screening trials: Commentary on the recent work by Olsen and Gøtzsche. *Cancer J Clin* 2002;52:68-71.
43. Duffy SW, Tabar L, Vitak B, Yen MF, Warwick J, Smith RA, et al. The Swedish Two-County Trial of mammographic screening: cluster randomisation and end point evaluation. *Ann Oncol* 2003;14:1196-8.
44. Editors T. When evidence collides with anecdote, politics, and emotion: breast cancer screening. *Ann Intern Med* 2010;152:531-2.
45. Eisinger F, Blay JY, Morere JF, Rixe O, Calazel-Benque A, Cals L, et al. Cancer screening in France: subjects' and physicians' attitudes. *Cancer Caus Contr* 2008;19:431-4.
46. Elmore J, Choe J. Breast cancer screening for women in their 40s: moving from controversy about data to helping individual women. *Ann Intern Med* 2007;146:529-31.
47. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. *JAMA* 2005;293:1245-56.
48. Elmore JG, Reisch LM, Barton MB, Barlow WE, Rolnick S, Harris EL, et al. Efficacy of breast cancer screening in the community according to risk level. *JNCI* 2005;97:1035-43.
49. Engel J, Eckel R, Kerr J, Schmidt M, Furstenberger G, Richter R, et al. The process of metastatisation for breast cancer. *Eur J Cancer* 2003;39:1794-806.

50. Engel J, Kerr J, Hoelzel D. Comment letter on Ole Olsen, Peter C. Gøtzsche Lancet 2001. Breast 2002;358:1340–2.
51. Erbas B, Amos A, Fletcher A, Kavanagh AM, Gertig DM. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: Should older women continue screening? Cancer Epi Biom 2004;13:1569-73.
52. Esserman L, Cowley H, Eberle C, Kirkpatrick A, Chang S, Berbaum K, et al. Improving the accuracy of mammography: Volume and outcome relationships. JNCI 2002;94:369-75.
53. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685-92.
54. Feig SA. Effect of service screening mammography on population mortality from breast carcinoma. Cancer 2002;95:451-7.
55. Finucane TE. Cost-effectiveness of mammography for older women. Ann Intern Med 2004;140:844.
56. Fletcher SW, Elmore JG. Mammographic screening for breast cancer. N Engl J Med 2003;348:1672-80.
57. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011;378:1461-84.
58. Fortunato L, Penteriani R, Farina M, Vitelli CE, Piro FR. Intraoperative ultrasound is an effective and preferable technique to localize non-palpable breast tumors. Eur J Surg Oncol 2008;34:1289-92.
59. Freedman DA, Petitti DB, Robins JM. On the efficacy of screening for breast cancer. Int J Epidemiol 2004;33:43-55.
60. Freedman DA, Petitti DB, Robins JM. Screening mammography: a decision analysis - Rejoinder. Int J Epidemiol 2004;33:69-73.
61. Freedman GM, Anderson PR, Goldstein LJ, Hanlon AL, Cianfrocca ME, Millenson MM, et al. Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older. Cancer 2003;98:918-25.
62. Freund KM, Dolan NC, Nelson HD. Update in women's health. Ann Intern Med 2003;138:119-27.
63. Ganz PA. Breast cancer 2002: Where do we stand? Cancer J Clin 2002;52:253-5.
64. Garcia RZ, Carvajal SC, Wilkinson AV, Thompson PA, Nodora JN, Komenaka IK, et al. Factors that influence mammography use and breast cancer detection among Mexican-American and African-American women. Cancer Caus Contr 2012;23:165-73.

65. Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. *JNCI* 2009;101:1216-20.
66. Gigerenzer G, Mata J, Frank R. Re: Public knowledge of benefits of breast and prostate cancer screening in Europe. *JNCI* 2010;102:356-7.
67. Goodman SN. The mammography dilemma: A crisis for evidence-based medicine? *Ann Intern Med* 2002;137:363-5.
68. Greif JM. Mammographic screening for breast cancer: An invited review of the benefits and costs. *Breast* 2010;19:268-72.
69. Grimes DA, Schulz KF. Uses and abuses of screening tests. *Lancet* 2002;359:881-4.
70. Gui GPH, Kadayaprath G, Darhouse N, Self J, Ward A, A'Hern R, et al. Clinical outcome and service implications of screening women at increased breast cancer risk from a family history. *Eur J Surg Onc* 2006;32:719-24.
71. Hackshaw AK, Paul EA. Breast self-examination and death from breast cancer: a meta-analysis. *Br J Cancer* 2003;88:1047-53.
72. Harper S, Lynch J, Meersman SC, Breen N, Davis WW, Reichman MC. Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005). *Cancer Epi Biom Prev* 2009;18:121-31.
73. Hemmer PHJ, Klasse JM, Mastboom WJB, Gerritsen JJGM, Mulder HJ, Volker EDP. The continued utility of needle localised biopsy for non-palpable breast lesions. *Eur J Surg Onc* 2004;30:10-4.
74. Henschke CI, Yankelevitz DF. CT screening for lung cancer. *Radiol Clin North Am* 2004;42:747-55.
75. Herr HW. Words of wisdom. Re: Rethinking screening for breast cancer and prostate cancer. *Eur Urol* 2010;57:540.
76. Hofvind SS, Wang H, Thoresen S. The Norwegian Breast Cancer Screening Program: re-attendance related to the women's experiences, intentions and previous screening result. *Cancer Causes Contr* 2003;14:391-8.
77. Humphrey LL, Helfand M, Chan BKS, Woolf SH. Breast cancer screening: A summary of the evidence for the US Preventive Services Task Force. *Ann Intern Med* 2002;137:347-60.
78. Jackson VP. Screening mammography: Controversies and headlines. *Radiology* 2002;225:323-6.
79. Jones BA, Dailey A, Calvocoressi L, Reams K, Kasl SV, Lee C, et al. Inadequate follow-up of abnormal screening mammograms: findings from the race differences in screening mammography process study (United States). *Cancer Causes Contr* 2005;16:809-21.

80. Juarbe TC, Kaplan CP, Somkin CP, Pasick R, Gildengorin G, Perez-Stable EJ. Are risk factors for breast cancer associated with follow-up procedures in diverse women with abnormal mammography? *Cancer Causes Contr* 2005;16:245-53.
81. Kacher DF, Jolesz FA. MR imaging--guided breast ablative therapy. *Radiol Clin North Am* 2004;42:947-62.
82. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. *N Engl J Med*. 2010;363:1203-10.
83. Keen JD. Non-mammographic screening for breast cancer. *JAMA* 2008;300:1515-6.
84. Kettritz U, Rotter K, Schreer I, Murauer M, Schulz-Wendtiand R, Peter D, et al. Stereotactic vacuum-assisted breast biopsy in 2874 patients - A Multicenter study. *Cancer* 2004;100:245-51.
85. Kinsinger LS, Harris R. Chemoprevention of breast cancer: a promising idea with an uncertain future. *Lancet* 2002;360:813-4.
86. Kmietowicz Z. WHO insists screening can cut breast cancer rates. *BMJ*. 2002;324(7339):695.
87. Koomen M, Pisano ED, Kuzmiak C, Pavic D, McLelland R. Future directions in breast imaging. *J Clin Oncol* 2005;23:1674-7.
88. Kopans DB. The most recent breast cancer screening controversy about whether mammographic screening benefits women at any age: Nonsense and nonscience. *Am J Roentgenol* 2003;180:21-6.
89. Kopans DB. The 2009 US Preventive Services Task Force (USPSTF) guidelines are not supported by science: the scientific support for mammography screening. *Radiol Clin North Am* 2010;48:843-57.
90. Kopans DB, Monsees B, Feig SA. Screening for cancer: When is it valid? - Lessons from the mammography experience. *Radiology* 2003;229:319-27.
91. Krekel NM, Zonderhuis BM, Stockmann HB, Schreurs WH, van der Veen H, de Lange de Klerk ES, et al. A comparison of three methods for nonpalpable breast cancer excision. *Eur J Surg Oncol* 2011;37:109-15.
92. Kriege M, Brekelmans CTM, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. *N Engl J Med* 2004;351:427-37.
93. Lampic C, Thurfjell E, Sjoden PO. The influence of a false-positive mammogram on a woman's subsequent behaviour for detecting breast cancer. *Eur J Cancer* 2003;39:1730-7.
94. Langhorne P. Screening mammography: setting the record straight. *Lancet* 2002;359:440.
95. Lawrence W. Editorial commentary: Screening mammography. *J Surg Oncol* 2002;81:159.

96. Leary A, Smith IE. Survival from breast cancer in England and Wales up to 2001 - Clinical commentary. *Br J Cancer* 2008;99:S56-S8.
97. Lee CH. Screening mammography: proven benefit, continued controversy. *Radiol Clin North Am* 2002;40:395-407.
98. Lee JH, Zuckerman D. Screening for breast cancer with mammography. *Lancet* 2001;358:2164-5.
99. Lee SJ, Zelen M. Modelling the early detection of breast cancer. *Ann Oncol* 2003;14:1199-202.
100. Luck AA, Evans AJ, James JJ, Rakha EA, Paish EC, Green AR, et al. Breast carcinoma with basal phenotype: Mammographic findings. *Am J Roentgenol* 2008;191:346-51.
101. Lyratzopoulos G, Barbiere JM, Rachet B, Baum M, Thompson MR, Coleman MP. Changes over time in socioeconomic inequalities in breast and rectal cancer survival in England and Wales during a 32-year period (1973-2004): the potential role of health care. *Ann Oncol* 2011;22:1661-6.
102. MacLennan AH, Lawton B, Baber RJ. Hormone replacement therapy and the breast - Studies must determine the evidence. *BMJ* 2002;324:915-6.
103. Mandelblatt J, Buist D. The elusive goal of maintaining population cancer screening: it is time for a new paradigm. *JNCI* 2010;102:998-9.
104. Mayor S. Row over breast cancer screening shows that scientists bring "some subjectivity into their work". *BMJ* 2001;323:956.
105. McCartney M. Medicine and the Media Selling health to the public *BMJ* 2010;341:c6639.
106. McLellan F. Independent US panel fans debate on mammography. *Lancet* 2002;359:409.
107. McPherson K. Should we screen for breast cancer? *BMJ* 2010;341:233-5.
108. Meissner HI, Klabunde CN, Han PK, Benard VB, Breen N. Breast cancer screening beliefs, recommendations and practices: primary care physicians in the United States. *Cancer* 2011;117:3101-11.
109. Meissner HI, Smith RA, Rimer BK, Wilson KM, Rakowski W, Vernon SW, et al. Promoting cancer screening: Learning from experience. *Cancer* 2004;101:1107-17.
110. Michaelson JS, Satija S, Kopans D, Moore R, Silverstein M, Comegno A, et al. Gauging the impact of breast carcinoma screening in terms of tumor size and death rate. *Cancer* 2003;98:2114-24.
111. Miettinen OS, Henschke CI, Pasmantier MW, Smith JP, Libby DM, Yankelevitz DF. Mammographic screening: no reliable supporting evidence? *Lancet* 2002;359:404-5.
112. Miller AB. Screening for breast cancer with mammography. *Lancet* 2001;358:2164.

113. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: Breast cancer mortality after 11 to 16 years of follow-up - A randomized screening trial of mammography in women age 40 to 49 years. *Ann Intern Med* 2002;137:305-12.
114. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. *Lancet* 2006;368:2053-60.
115. Mulshine JL. Commentary: lung cancer screening--progress or peril. *Oncologist* 2008;13:435-8.
116. Nelson HD, Humphrey L, Tyne K. Re: The background review for the USPSTF recommendation on screening for breast cancer. *Ann Intern Med* 2010;152:537-8.
117. Newman DH. Screening for breast and prostate cancers: moving toward transparency. *JNCI* 2010;102:1008-11.
118. Niederhuber JE. Seeking calmer waters in a sea of controversy. *Oncologist* 2002;7:172-3.
119. Nystrom L, Andersson I, Bjurstam N, Frisell J, Rutqvist LE. Update on effects of screening mammography - Reply. *Lancet* 2002;360:339-40.
120. Olsen AH, Njor SH, Vejborg I, Schwartz W, Dalgaard P, Jensen MB, et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. *Brit Med J* 2005;330:220-2A.
121. Paci E, Coviello E, Miccinesi G, Puliti D, Cortesi L, De Lisi V, et al. Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis. *Eur J Cancer* 2008;44:858-65.
122. Paci E, Duffy SW, Giorgi D, Zappa M, Crocetti E, Vezzosi V, et al. Are breast cancer screening programmes increasing rates of mastectomy? Observational study. *BMJ* 2002;325:418.
123. Ponzzone R, Sismondi P, Baum M. Beyond randomized controlled trials - Organized mammographic screening substantially reduces breast carcinoma mortality. *Cancer* 2002;94:579-80.
124. Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK. Screening mammography for women 40 to 49 years of age: A clinical practice guideline from the American College of Physicians. *Ann Intern Med* 2007;146:511-5.
125. Quinn MJ. Cancer trends in the United States - A view from Europe. *JNCI* 2003;95:1258-61.
126. Rakowski W, Breslau ES. Perspectives on behavioral and social science research on cancer screening. *Cancer* 2004;101:1118-30.
127. Rayter Z, Kutt E. Overdiagnosis of breast cancer in screening. *Ejso-Eur J Surg Onc* 2004;30:711-2.
128. Rickard M, Taylor R, Page A, Estoesta J. Cancer detection and mammogram volume of radiologists in a population-based screening programme. *Breast*. 2006;15:39-43.



129. Rogers LF. Screening mammography: Target of opportunity for the media. *Am J Roentgenol* 2003;180:1.
130. Rosenberg L, Wise LA, Palmer JR, Horton NJ, Adams-Campbell LL. A multilevel study of socioeconomic predictors of regular mammography use among African-American women. *Cancer Epidemiol Biom* 2005;14:2628-33.
131. Rossi PG, Federici A, Farchi S, Chini F, Barca A, Guasticchi G, et al. The effect of screening programmes on the treatment of benign breast neoplasms: observations from current practice in Italy. *J Med Screen* 2006;13:123-8.
132. Rozenberg S, Ham H, Liebens F. Screening for breast cancer with mammography. *Lancet* 2001;358:2167.
133. Schopper D, de Wolf C. How effective are breast cancer screening programmes by mammography? Review of the current evidence. *Eur J Cancer* 2009;45:1916-23.
134. Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. *Ann Intern Med* 2011;155:10-20.
135. Schwartz LM, Woloshin S. News media coverage of screening mammography for women in their 40s and tamoxifen for primary prevention of breast cancer. *JAMA* 2002;287:3136-42.
136. Schwartz LM, Woloshin S, Fowler FJ, Welch HG. Enthusiasm for cancer screening in the United States. *JAMA* 2004;291:71-8.
137. Senn S. Screening for breast cancer with mammography. *Lancet* 2001;358:2165.
138. Sherman ME, Howatt W, Blows FM, Pharoah P, Hewitt SM, Garcia-Closas M. Molecular pathology in epidemiologic studies: a primer on key considerations. *Cancer Epidemiol Bio Prev* 2010;19:966-72.
139. Simes J, Wilcken N, Brunswick C, Clarke M, Ganz P, Ghersi D, et al. Screening mammography: setting the record straight. *Lancet* 2002;359:439-40.
140. Sistrom CL. The Appropriateness of Imaging: A Comprehensive Conceptual Framework. *Radiology* 2009;251:637-49.
141. Smith JA, Andreopoulou E. An overview of the status of imaging screening technology for breast cancer. *Ann Oncol* 2004;15:118-126.
142. Smith R, Duffy S, Tabar L. The mammographic screening trials: Commentary on the recent work by Olsen and Gøtzsche. *J Surg Oncol* 2002;81:164-6.
143. Smith RA. The ongoing evaluation of breast cancer screening. *Cancer* 2004;100:1327-30.
144. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. *Ca-Cancer J Clin* 2003;53:27-43.

145. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, et al. American Cancer Society guidelines for the early detection of cancer. *Ca-Cancer J Clin* 2002;52:8-22.
146. Smith RA, Duffy SW, Gabe R, Tabar L, Yen AM, Chen TH. The randomized trials of breast cancer screening: what have we learned? *Rad Clin North Am* 2004;42:793-806.
147. Smith RA, Saslow D, Sawyer KA, Burke W, Costanza ME, Evans WP, et al. American cancer society guidelines for breast cancer screening: Update 2003. *Ca-Cancer J Clin* 2003;53:141-69.
148. Sox H. Screening mammography for younger women: Back to basics. *Ann Intern Med* 2002;137:361-2.
149. Stojadinovic A, Nissan A, Gallimidi Z, Lenington S, Logan W, Zuley M, et al. Electrical impedance scanning for the early detection of breast cancer in young women: Preliminary results of a multicenter prospective clinical trial. *J Clin Oncol* 2005;23:2703-15.
150. Tabar L, Duffy SW, Yen MF, Warwick J, Vitak B, Chen HH, et al. All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. *J Med Screen* 2002;9:159-62.
151. Tabar L, Yen MF, Vitak B, Chen HHT, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. *Lancet* 2003;361:1405-10.
152. Thornton H. Screening for breast cancer with mammography. *Lancet*. 2001;358:2165.
153. Thornton H. Breast screening seems driven by belief rather than evidence. *BMJ* 2002;324:677.
154. Thornton H. The screening debates: time for a broader approach? *Eur J Cancer*. 2003;39:1807-9.
155. Tice JA, Feldman MD. Full-field digital mammography compared with screen-film mammography in the detection of breast cancer: rays of light through DMIST or more fog? *Breast Cancer Res Treat* 2008;107:157-65.
156. Turner NC, Jones AL. Management of breast cancer--part I. *BMJ* 2008;337:a421.
157. Uematsu T, Yuen S, Kasami M, Uchida Y. Dynamic contrast-enhanced MR imaging in screening detected microcalcification lesions of the breast: is there any value? *Breast Cancer Res Treat* 2007;103:269-81.
158. Vaidya JS. Screening for breast cancer with mammography. *Lancet*. 2001;358:2166.
159. van Veen WA, Knottnerus JA. Screening mammography. *Lancet*. 2002;359:1701.
160. von Eschenbach AC. NCI remains committed to current mammography guidelines. *Oncologist* 2002;7:170-1.

161. Weir HK, Thun MJ, Hankey BF, Ries LAG, Howe HL, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. *JNCI* 2003;95:1276-99.
162. Woloshin S, Schwartz LM. Numbers needed to decide. *JNCI* 2009;101:1163-5.
163. Woloshin S, Schwartz LM. The benefits and harms of mammography screening: understanding the trade-offs. *JAMA* 2010;303:164-5.
164. Yankelevitz DF. Screening for a cancer: Acting on social responsibility. *Am J Roentgenol* 2007;188:1171-2.
165. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. *JNCI* 2002;94:958-60.
166. Yasunaga H, Ide H, Imamura T, Ohe K. Women's anxieties caused by false positives in mammography screening: a contingent valuation survey. *Breast Cancer Res Treat* 2007;101:59-64.
167. Yu YH, Liang C, Yuan XZ. Diagnostic value of vacuum-assisted breast biopsy for breast carcinoma: a meta-analysis and systematic review. *Breast Cancer Res Treat* 2010;120:469-79.
168. Zackrisson S, Janzon L, Manjer J, Andersson I. Improved survival rate for women with interval breast cancer - results from the breast cancer screening programme in Malmo, Sweden 1976-1999. *J Med Screen*. 2007;14:138-43.
169. Zahl PH. Overdiagnosis of breast cancer in Denmark. *Br J Cancer* 2004;90:1686.
170. Zahl PH. An inverse association between tumour size and overdiagnosis may explain the results by Bucchi et al. *Br J Cancer* 2005;92:1814.
171. Zahl PH, Strand H, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. *BMJ* 2004;328:921-4.